STRO实时信号 | 通过Getagraph.com最大化利润

购买 107561 min ago

@ $4.45

发出时间: 15 Feb 2024 @ 02:11

回报率: -23.16%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -4.28 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	474 120
平均成交量	999 409
市值	263.07M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.910 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.920
ATR14	$0.00500 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Srinivasan Venkatesh	Sell	21 250	Restricted Stock Unit (RSU)
2024-04-11	Srinivasan Venkatesh	Buy	21 250	Common Stock
2024-04-11	Srinivasan Venkatesh	Sell	7 582	Common Stock
2024-03-05	Newell William J	Buy	167 000	Restricted Stock Units (RSUs)
2024-03-05	Fitzpatrick Linda A	Buy	37 100	Restricted Stock Units (RSUs)

INSIDER POWER
67.78
Last 99 transactions
Buy: 2 171 384 \| Sell: 404 320

音量相关性

長: -0.47 (neutral)

短: -0.20 (neutral)

Signal:(20.299) Neutral

Sutro Biopharma Inc 相关性

10 最正相关
TNGX	0.88
CARA	0.864
EYE	0.821
SLM	0.809
ACHC	0.801
LSXMK	0.801

10 最负相关
ALR	-0.839
INZY	-0.833
BTBD	-0.83
INOD	-0.828
GETVV	-0.826
HYPR	-0.824
FTIV	-0.812
OCUL	-0.803
SELF	-0.802

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sutro Biopharma Inc 相关性 - 货币/商品

0.69
( moderate )

0.74
( moderate )

0.00
( neutral )

0.54
( weak )

-0.51
( weak negative )

Sutro Biopharma Inc 财务报表

Annual	2023
营收:	$153.73M
毛利润:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2023
营收:	$153.73M
毛利润:	$146.92M (95.57 %)
EPS:	$-1.780

FY	2022
营收:	$67.77M
毛利润:	$59.48M (87.77 %)
EPS:	$-2.35

FY	2021
营收:	$61.88M
毛利润:	$61.88M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.